Journal Logo

September 2022 - Volume 80 - Issue 3

  • George W. Booz, PhD, FAHA
  • 0160-2446
  • 1533-4023
  • 12 issues per year
  • Cardiac & Cardiovascular Systems 75/143, Pharmacology & Pharmacy 162/279
  • 3.271

G Protein Coupled Receptors - receptors with new tricks up their sleeves (Susan F. Steinberg and George W. Booz) G protein receptors (GPCRs) continue to fascinate and confound. Since 2012 when Brian Kobilka and Robert Lefkowitz received the Nobel Prize in Chemistry for their pioneering work on the beta-adrenergic receptor structure, GPCRs have been the subject of over 9,250 articles appearing on PubMed. Approximately 13% of these deal with drug discovery or development. Overall, about 35% of all Food and Drug Administration approved small molecule drugs target GPCRs. Yet many fundamental features of signaling by GPCR family members, including the dynamics and mechanisms that fine-tune their interactions with heterotrimeric G proteins and other binding partners and the functional consequences of various modes of GPCR activation, have only recently been exposed. This issue of the Journal of Cardiovascular Pharmacology contains a special series entitled Cardiovascular Regulation by GPCRs organized by one of us (Susan Steinberg) that includes 7 outstanding invited review articles, each entry updating a different recent development pertaining to a novel aspect of GPCR biology.
 ​

Current Issue Highlights






2021 Twitter logo - blue.pnglinkedinlogo.png

The editors of JCVP are calling for the submission of review articles dealing with all aspects of ER signaling in the heart, including the cGAS–cGAMP–STING pathway, mitochondria associated membranes, unfolded protein response (UPR), inflammasome activation, and ER stress. Articles with a therapeutic and disease-based perspective are welcomed. All articles will undergo peer review and appear in a regular issue in early 2023. Please contact the editorial office for additional information and prior approval for submission. ​​

The Journal of Cardiovascular Pharmacology announces an open call for a new review series dealing with the rapidly developing topic of RNA-based therapies. Reviews should focus on treating cardiovascular diseases or disorders, such as myocardial infarction, cardiac hypertrophy, cardiomyopathies, arrhythmias, valvular heart disease, aortic aneurysms, atherosclerosis and dysliidemia, and cerebrovascular disease. Various approaches, such as RNA aptamers, long non-coding RNAs, microRNAs, antisense nucleotides, and novel delivery strategies are included. The series is scheduled to appear early 2023. Please contact the editorial office for additional information and prior approval for submission.​​